Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany.

Olivieri M, Königs C, Heller C, Horneff S, Oldenburg J, Halimeh S, Kentouche K, Knöfler R, Fischer L, Pfrepper C, Kurnik K, Bidlingmaier C.

Hamostaseologie. 2019 Feb 5. doi: 10.1055/s-0039-1677874. [Epub ahead of print]

PMID:
30722069
2.

The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH.

Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A; subcommittee on factor viii, factor ix and rare coagulation disorders.

J Thromb Haemost. 2018 Oct;16(10):2106-2110. doi: 10.1111/jth.14257. Epub 2018 Sep 5. No abstract available.

PMID:
30182468
3.

Prospects for research in haemophilia with real-world data-An analysis of German registry and secondary data.

Schopohl D, Bidlingmaier C, Herzig D, Klamroth R, Kurnik K, Rublee D, Schramm W, Schwarzkopf L, Berger K.

Haemophilia. 2018 Jul;24(4):584-594. doi: 10.1111/hae.13443. Epub 2018 Feb 28.

PMID:
29488669
4.

Purpura fulminans - It's Not Always Sepsis.

Olivieri M, Huetker S, Kurnik K, Bidlingmaier C, Keil J, Reiter K, Hoffmann F.

Klin Padiatr. 2018 Jul;230(4):225-226. doi: 10.1055/s-0044-100620. Epub 2018 Jan 30. No abstract available.

PMID:
29381878
5.

Perioperative management of hemostasis in children and adolescents.

Bidlingmaier C, Olivieri M, Hütker S, Dietl S, Kurnik K.

Blood Cells Mol Dis. 2017 Sep;67:91-95. doi: 10.1016/j.bcmd.2017.01.009. Epub 2017 Jan 16. Review.

PMID:
28130047
6.

[The remains of the day: A working day in a university children's hospital].

Heinen F, Landgraf MN, Böhmer J, Borggräfe I, Bidlingmaier C, Krohn K, Hoffmann F, Nicolai T, Weigl M, von Kries R, Albers L.

Z Evid Fortbild Qual Gesundhwes. 2016 Nov;117:20-26. doi: 10.1016/j.zefq.2016.09.002. Epub 2016 Sep 30. German.

7.

Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study.

James PD, Mahlangu J, Bidlingmaier C, Mingot-Castellano ME, Chitlur M, Fogarty PF, Cuker A, Mancuso ME, Holme PA, Grabell J, Satkunam N, Hopman WM, Mathew P; Global Emerging HEmostasis Experts Panel (GEHEP).

Haemophilia. 2016 Nov;22(6):912-918. doi: 10.1111/hae.13089.

PMID:
27868369
8.

Ultrasound Assisted Endovascular Thrombolysis in Adolescents: 2 Case Reports.

Olivieri M, Kurnik K, Hoffmann F, Reiter K, Bidlingmaier C, Kuhlencordt P, Treitl M.

Pediatrics. 2016 Jul;138(1). pii: e20160022. doi: 10.1542/peds.2016-0022. Epub 2016 Jun 9.

9.

[Haemostatic disorders in children].

Kurnik K, Bidlingmaier C, Hütker S, Olivieri M.

Hamostaseologie. 2016 May 10;36(2):109-25. doi: 10.5482/HAMO-15-04-0016. Epub 2016 Mar 18. Review. German.

PMID:
26988657
10.

Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey.

Fogarty PF, Mancuso ME, Kasthuri R, Bidlingmaier C, Chitlur M, Gomez K, Holme PA, James P, Kruse-Jarres R, Mahlangu J, Mingot-Castellano ME, Soni A; Global Emerging Hemophilia Panel (GEHEP).

Haemophilia. 2015 Sep;21(5):589-97. doi: 10.1111/hae.12652. Epub 2015 Feb 17.

PMID:
25689278
11.

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.

Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U.

Thromb Haemost. 2015 May;113(5):958-67. doi: 10.1160/TH14-07-0621. Epub 2015 Jan 29.

PMID:
25631402
12.

Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study.

Kenet G, Bidlingmaier C, Bogdanova N, Ettingshausen CE, Goldenberg N, Gutsche S, Halimeh S, Holzhauer S, Kurnik K, Limperger V, Junker R, Nowak-Göttl U.

Thromb Res. 2014 Apr;133(4):544-9. doi: 10.1016/j.thromres.2014.01.005. Epub 2014 Jan 17.

13.

Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment.

James P, Kasthuri R, Kruse-Jarres R, Soni A, Kulkarni R, Bidlingmaier C, Chitlur M, Fogarty P, Gomez K, Holm PA, Mahlangu J, Mancuso ME, Mingot-Castellano ME, Dolan G.

Transfus Med Hemother. 2013 Oct;40(5):352-5. doi: 10.1159/000354843. Epub 2013 Aug 26. Review.

14.

Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.

Halimeh S, Bidlingmaier C, Heller C, Gutsche S, Holzhauer S, Kenet G, Kurnik K, Manner D, Iorio A, Nowak-Göttl U.

Biomed Res Int. 2013;2013:901975. doi: 10.1155/2013/901975. Epub 2013 Oct 2.

15.

Novel mutation in Hermansky-Pudlak syndrome type 2 with mild immunological phenotype.

Kurnik K, Bartsch I, Maul-Pavicic A, Ehl S, Sandrock-Lang K, Bidlingmaier C, Rombach N, Busse A, Belohradsky BH, Müller-Höcker J, Aslanidis C, Schmitz G, Zieger B.

Platelets. 2013;24(7):538-43. doi: 10.3109/09537104.2012.741275. Epub 2012 Dec 5.

PMID:
23215637
16.

Arterial thrombosis in homozygous antithrombin deficiency.

Olivieri M, Bidlingmaier C, Schetzeck S, Borggräfe I, Geisen C, Kurnik K.

Hamostaseologie. 2012;32 Suppl 1:S79-82.

PMID:
22961244
17.

[Acute abdominal pain in children].

Krohn K, Heinrich M, Teusch V, Bidlingmaier C.

MMW Fortschr Med. 2012 Mar 8;154(4):47-50, 52. German. No abstract available.

PMID:
22619838
18.

Prospective evaluation of a pediatric bleeding questionnaire and the ISTH bleeding assessment tool in children and parents in routine clinical practice.

Bidlingmaier C, Grote V, Budde U, Olivieri M, Kurnik K.

J Thromb Haemost. 2012 Jul;10(7):1335-41. doi: 10.1111/j.1538-7836.2012.04775.x.

19.

Repeated coagulation testing in children. Does it improve the diagnostic value?

Bidlingmaier C, Treutwein J, Olivieri M, Kurnik K.

Hamostaseologie. 2011 Nov;31 Suppl 1:S51-6.

PMID:
22057912
20.

Inhibitor-immunology-study. Evaluation of inhibitor development in haemophilia B.

Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Eberl W, Kemkes-Matthes B, Bidlingmaier C, Kurnik K, Lischetzki G, Nimtz-Talaska A, Eisert R, Bogdanova N, Doerk T, Sykora KW.

Hamostaseologie. 2011 Nov;31 Suppl 1:S57-60.

PMID:
22057736
21.

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.

Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, Pergantou H, Platokouki H, Giangrande P, Peerlinck K, Celkan T, Ozdemir N, Bidlingmaier C, Ingerslev J, Giansily-Blaizot M, Schved JF, Gilmore R, Gadisseur A, Benedik-Dolničar M, Kitanovski L, Mikovic D, Musallam KM, Rosendaal FR; European Network of Rare Bleeding Disorders Group.

J Thromb Haemost. 2012 Apr;10(4):615-21. doi: 10.1111/j.1538-7836.2012.04653.x.

22.

Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies.

Bidlingmaier C, Kenet G, Kurnik K, Mathew P, Manner D, Mitchell L, Krümpel A, Nowak-Göttl U.

Semin Thromb Hemost. 2011 Oct;37(7):814-25. doi: 10.1055/s-0031-1297173. Epub 2011 Dec 20. Review.

PMID:
22187405
23.

Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis.

Olivieri M, Kurnik K, Pfluger T, Bidlingmaier C.

Haemophilia. 2012 May;18(3):369-74. doi: 10.1111/j.1365-2516.2011.02682.x. Epub 2011 Oct 28.

PMID:
22032268
24.

Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience.

Auerswald G, Bidlingmaier C, Kurnik K.

Haemophilia. 2012 Jan;18(1):e18-20. doi: 10.1111/j.1365-2516.2011.02659.x. Epub 2011 Sep 27. No abstract available.

PMID:
21951822
25.

Management of pregnancy and delivery in women with inherited bleeding disorders.

Peyvandi F, Bidlingmaier C, Garagiola I.

Semin Fetal Neonatal Med. 2011 Dec;16(6):311-7. doi: 10.1016/j.siny.2011.07.006. Epub 2011 Aug 17. Review.

PMID:
21852211
26.

Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.

Bidlingmaier C, Kurnik K, Escuriola-Ettingshausen C, Jager R, Klamroth R, Male C, Marosi A, Nemes L, von Stackelberg A, Kreuz W.

Haemophilia. 2011 Sep;17(5):e837-40. doi: 10.1111/j.1365-2516.2011.02577.x. Epub 2011 Jun 7. No abstract available.

PMID:
21649797
27.

Postoperative bleeding in paediatric ENT surgery. First results of the German ESPED trial.

Bidlingmaier C, Olivieri M, Stelter K, Eberl W, von Kries R, Kurnik K.

Hamostaseologie. 2010 Nov;30 Suppl 1:S108-11.

PMID:
21042683
28.

Heterozygous SOX9 mutations allowing for residual DNA-binding and transcriptional activation lead to the acampomelic variant of campomelic dysplasia.

Staffler A, Hammel M, Wahlbuhl M, Bidlingmaier C, Flemmer AW, Pagel P, Nicolai T, Wegner M, Holzinger A.

Hum Mutat. 2010 Jun;31(6):E1436-44. doi: 10.1002/humu.21238.

PMID:
20513132
29.

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.

Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U.

J Thromb Haemost. 2010 Jun;8(6):1256-65. doi: 10.1111/j.1538-7836.2010.03823.x. Epub 2010 Mar 17. Review.

30.

Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.

Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, Bidlingmaier C, Frühwald MC, Heller C, Schmidt W, Pautard B, Nowak-Göttl U.

Blood. 2010 Jun 17;115(24):4999-5004. doi: 10.1182/blood-2010-01-263012. Epub 2010 Mar 25.

31.

New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.

Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G.

Haemophilia. 2010 Mar;16(2):256-62. doi: 10.1111/j.1365-2516.2009.02122.x. Epub 2009 Oct 29.

PMID:
19878331
32.

Coagulation testing in the evaluation of suspected child abuse.

Olivieri M, Kurnik K, Bidlingmaier C.

Hamostaseologie. 2009 May;29(2):190-2.

PMID:
19404515
33.

Haemostatic testing prior to elective surgery in children? Not always!

Bidlingmaier C, Eberl W, Knöfler R, Olivieri M, Kurnik K.

Hamostaseologie. 2009 Jan;29(1):64-7.

PMID:
19151849
34.

Inhibitor-Immunology-Study. Different HLA-types seem to be involved in the inhibitor development in haemophilia A.

Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Bidlingmaier C, Kurnik K, Nimtz-Talaska A, Niekrens C, Eisert R, Tiede A, Ebenebe C, Lakomek M, Hoy L, Welte K, Sykora KW.

Hamostaseologie. 2008 Oct;28 Suppl 1:S26-8.

PMID:
18958335
35.

Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.

Schobess R, Kurnik K, Friedrichs F, Halimeh S, Krümpel A, Bidlingmaier C, Nowak-Göttl U.

Thromb Haemost. 2008 Jan;99(1):71-6. doi: 10.1160/TH07-06-0417.

PMID:
18217137
36.

Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children.

Nowak-Göttl U, Bidlingmaier C, Krümpel A, Göttl L, Kenet G.

Br J Pharmacol. 2008 Mar;153(6):1120-7. Epub 2007 Oct 1. Review.

37.
38.

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys.

Kurnik K, Kreuz W, Horneff S, Düring C, Schobess R, Bidlingmaier C, Ettingshausen CE, Krümpel A, Bogdanova N, Nowak-Göttl U.

Haematologica. 2007 Jul;92(7):982-5.

39.

Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study.

Kenet G, Kirkham F, Niederstadt T, Heinecke A, Saunders D, Stoll M, Brenner B, Bidlingmaier C, Heller C, Knöfler R, Schobess R, Zieger B, Sébire G, Nowak-Göttl U; European Thromboses Study Group.

Lancet Neurol. 2007 Jul;6(7):595-603.

40.
41.

Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.

Bidlingmaier C, Deml MM, Kurnik K.

Haemophilia. 2006 May;12(3):212-7.

PMID:
16643203
42.

Safety and efficacy of danaparoid (Orgaran) use in children.

Bidlingmaier C, Magnani HN, Girisch M, Kurnik K.

Acta Haematol. 2006;115(3-4):237-47.

PMID:
16549902
43.

Intracellular T-cell cytokine levels are age-dependent in healthy children and adults.

Hoffmann F, Albert MH, Arenz S, Bidlingmaier C, Berkowicz N, Sedlaczek S, Till H, Pawlita I, Renner ED, Weiss M, Belohradsky BH.

Eur Cytokine Netw. 2005 Dec;16(4):283-8.

44.

Thromboembolism in neonates and infants: impact of underlying diseases, prothrombotic risk factors and treatment modalities.

Kurnik K, Duering C, Bidlingmaier C, Nowak-Göttl U.

Thromb Res. 2005 Feb;115 Suppl 1:71-7. No abstract available.

PMID:
15790161
45.

Haemophilia A in two premature infants.

Bidlingmaier C, Bergmann F, Kurnik K.

Eur J Pediatr. 2005 Feb;164(2):70-2. Epub 2004 Dec 3.

PMID:
15580358
46.

Growth hormone (GH) insensitivity syndrome due to a GH receptor truncated after Box1, resulting in isolated failure of STAT 5 signal transduction.

Milward A, Metherell L, Maamra M, Barahona MJ, Wilkinson IR, Camacho-Hübner C, Savage MO, Bidlingmaier M, Clark AJ, Ross RJ, Webb SM.

J Clin Endocrinol Metab. 2004 Mar;89(3):1259-66. Erratum in: J Clin Endocrinol Metab. 2009 Jul;94(7):2674. Bidlingmaier, C M [corrected to Bidlingmaier, M].

PMID:
15001620
47.

Adenosine kinase inhibitor GP515 improves experimental colitis in mice.

Siegmund B, Rieder F, Albrich S, Wolf K, Bidlingmaier C, Firestein GS, Boyle D, Lehr HA, Loher F, Hartmann G, Endres S, Eigler A.

J Pharmacol Exp Ther. 2001 Jan;296(1):99-105.

PMID:
11123368
48.

High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein.

Hartmann G, Tschöp M, Fischer R, Bidlingmaier C, Riepl R, Tschöp K, Hautmann H, Endres S, Toepfer M.

Cytokine. 2000 Mar;12(3):246-52.

PMID:
10704252
49.

Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.

Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, Eigler A, Lehr HA, Endres S.

J Pharmacol Exp Ther. 2000 Jan;292(1):22-30.

PMID:
10604928
50.

Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) I beta and IL-I receptor antagonist gene polymorphisms.

Hacker UT, Bidlingmaier C, Gomolka M, Keller E, Eigler A, Hartmann G, Folwaczny C, Fricke H, Albert E, Loeschke K, Endres S.

Eur J Clin Invest. 1998 Mar;28(3):214-9.

PMID:
9568467

Supplemental Content

Loading ...
Support Center